ABSTRACT
Traditionally, preimplantation genetic testing (PGT) for in vitro fertilization (IVF) requires invasive trophectoderm (TE) biopsy, which might be detrimental to the embryo. Recently proposed non-invasive PGT (ni-PGT) utilizing cell-free DNA from spent embryo culture medium (SCM) also faces serious challenges in accuracy, especially for monogenic diseases (niPGT-M), due to trace DNA content, maternal cell contamination, and high Allele Drop-Out (ADO) rates. In this study, an improved linear single-cell whole genome amplification method and a Bayesian linkage analysis model were used to enhance accuracy in niPGT-M. We achieved about 75% report rate across all samples and 100% accuracy in the reported samples. Meanwhile, we reconstructed the embryonic genome and calculated the risk of type II diabetes (T2D) via niPGT-P, consistent well with those from TE biopsy samples. Our approach alleviated the limitations of ni-PGT and offers a promising avenue for advancing noninvasive PGT with potential clinical applications.
Competing Interest Statement
L.H., H.G., R.Z. and X.S.X. are coinventors on patent application PCT/CN2023/125605 that includes the experimental discovery and BASE-niPGT-M in this manuscript. S.L., Y.Z. and Y.X. are current employees of Yikon Genomics.
Funding Statement
This work is funded by Beijing Advanced Innovation Center for Genomics at Peking University and Changping Laboratory. H.G. is supported by National Natural Science Fundation of China (No. 11971037 and T2225001). This study was also supported by the National Key R&D Program of China (2023YFC2705604), the National Science Foundation of China (82071721 and 82371706) and the special fund of the National Clinical Key Specialty Construction Program, P. R. China (2023).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Peking University Third Hospital Ethical Review Committee (Approval no. 2020SZ-005). The patients/participants provided written informed consent to participate in this study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
DATA AVAILABILITY
Access to anonymized patient data is subject to a data-sharing agreement and protocol approval from the institutional review board committee. The study-specific analyzable dataset is, therefore, not publicly available. All summary statistics are available in Supplementary Tables.
